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Atrial natriuretic peptide in dehydrated Lung—Evans rats and Brat-
tieboro rats. Atrial natriuretic peptide (ANP) was measured by radio-
immunoassay in atrial and plasma extracts from normal Long—Evans
(LE) rats and Brattleboro-strain diabetes insipidus (DI) rats. LE rats,
dehydrated for 72 hours, had an increased plasma osmolality and
plasma vasopressin. They also demonstrated a higher atrial im-
munoreactive ANP (1R-ANP) content than hydrated animals (72 hr
dehydration: 178.2 30.4 g/g wet weight atria, mean SE, control:
60.4 8.2; P < 0.001). Plasma IR-ANP in dehydrated LE rats tended
to be lower than hydrated LE but this was not statistically significant
[72 hr dehydration: 61.9 5.9 pg/mI, control: 82.4 8.2]. IR-ANP
concentration in atrial extracts from Dl rats, without detectable plasma
vasopressin levels but with increased plasma osmolality, was not
different from that in hydrated LE rats (Dl: 100.6 13.2 tg/g). There
was also no significant difference between plasma IR-ANP in Dl and
hydrated LE rats (Dl: 100.2 11.9 pg/mI). The atrial IR-ANP concen-
tration in DL rats was decreased by infusion with either arginine—
vasopressin (AVP) or I -deamino-8-arginine vasopressin (DDAVP), and
plasma IR-ANP was increased significantly by both infusions (AVP:
171.3 18.1 pg/mI, DDAVP: 179.5 24.6). Thus, changes in atrial and
plasma IR-ANP concentration appeared to be associated with changes
in water balance but not with plasma AVP levels, indicating that the
changes in volume may be a more important factor controlling ANP
release in vivo than vasopressin itself.
The atrium of the heart contains peptides, which show potent
diuretic, natriuretic and smooth muscle relaxing activities [1, 21.
These peptides, termed atrial natriuretic peptide (ANP), are
stored in granules [3—5]. The granule content of the atrium
varies with fluid and salt balance and it has been postulated that
the atrium may act as a volume sensor and respond by releasing
ANP [5, 61. ANP has been purified and its amino acid sequence
determined [7, 81. Furthermore, peptides with the amino acid
sequence of native ANP have been synthesized, and their
natriuretic activity and smooth muscle relaxing activities shown
to be identical to native ANP [9—11]. The major circulating form
of ANP is now thought to be the 28 amino acid form (a-atrial
natriuretic peptide) and recently radioimmunoassays of ANP in
plasma and atrial extracts have been developed [12, 13].
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Argininet—vasopressin (AVP) has antidiuretic and vascular
smooth muscle constricting activities [141, and has been dem-
onstrated to play a significant role in maintaining plasma
osmolality, sodium concentration, extracellular fluid volume
and blood pressure [15, 16]. Some of these actions are opposite
to those of ANP. Low pressure receptors in the atria have long
been known to play an important role in suppressing vasopres-
sin release [17]. In contrast, volume loading has recently been
shown to increase ANP release, causing a rise in plasma ANP
[18]. ANP messenger RNA has been shown to decrease after
dehydration [191. The opposing effects of dehydration on AVP
and ANP together with their opposite physiological actions
suggests the possibility of some interaction between the two
peptides.
In volume loading when AVP is suppressed, plasma ANP is
increased. In contrast, in volume depletion when plasma AVP
is stimulated, plasma ANP tends to decrease. Thus there is a
possibility that AVP may regulate ANF release from the heart.
Alternatively, these hormonal changes may be secondary to
volume change and changes in atrial pressure/volume or
stretch.
The Brattleboro (DI) rat has genetic hypothalamic diabetes—
insipidus. It has a large urinary output and water intake with a
high plasma sodium and osmolality [201. It therefore offers a
convenient model to manipulate volume and vasopressin inde-
pendently and to elucidate the role of AVP and volume in the
control of ANF release. This paper compares plasma and atrial
ANF levels in hydrated and dehydrated Long—Evans (LE) rats
to Brattleboro (DI) rats. ANF levels were also measured in
Brattleboro rats after correction of water balance with
exogenous AVP or DDAVP infusions. The results show that
ANF levels are regulated by changes in fluid volume rather than
hormone levels.
Methods
Normal and dehydrated Long—Evans rats
Male Long—Evans (LE) rats weighing 250 to 300 g were used
throughout the study. Rats (N = 6) were dehydrated for 72
hours. Control (N = 12) and dehydrated rats were then weighed
and decapitated. Trunk blood was collected through a chilled
heparinized funnel into ice—cold heparinized tubes for AVP
radioimmunoassay [21] and into tubes containing aprotinin (500
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KIU/mi, Bayer), soybean trypsin inhibitor (0.01 mg/mI, Sigma
Type 1-S) and EDTA (I mg/mi) [221 for radioimmunoassay of
ANP, and renin activity.
Brattleboro rats infused with A VP or DDAVP
Male Brattleboro rats (DI rats) weighing 225 to 300 g were
used throughout the study. All rats were housed in individual
metabolic cages and urine flow and water intake were moni-
tored daily. After a control period of three days, the rats were
anaesthetized with ether and minipumps were implanted in the
peritoneal space. Rats were divided into three groups. Control
DI rats (N = 12) were operated and given normal saiine via
osmotic minipumps at 1 pA/h for seven days. A second group of
DI rats (N = 12) were infused with 2.0 ng/kg/min of synthetic
AVP via osmotic minipumps. A third group of DI rats (N = 12)
were similarly infused with l-deamino-8-D-arginine vasopressin
(DDAVP) also at a dose of 2.0 ng/kg/min. After four days of
equilibration, all rats were again housed in individual metabolic
cages, and urine flow and water intake were monitored for three
days. Finally the rats were killed on the seventh day, and the
blood was collected by the methods described above.
Preparation of the plasma and atrial samples for ANP
measurements
Rat immunoreactive ANP was extracted from plasma using
Vycor glass. To I ml fresh plasma 30 mg of Vycor glass (140
mesh) was added and vortexed for 30 minutes at 4°C. After two
minutes centrifugation the supernatant was aspirated and the
glass powder was washed twice with 2 ml water. The absorbed
ANP was extracted from the glass powder with I ml of 60%
acetone containing 0.1% trifluoroacetic acid during 30 minute
vortexing at 4°C. After a short centrifugation, the supernatant
was evaporated under an air stream and the extract was
resuspended in the buffer used for radioimmunoassay. Recov-
ery of added synthetic a-rat atrial natriuretic peptide (a-rANP,
Peptide Institute Inc., Japan) (15 to 2000 pg) from rat plasma,
using the same procedure as above, was 94.0 2.5% (mean
SE, N = 8). Immediately after the blood sampling, the atria and
ventricles were dissected and weighed. For the measurement of
immunoreactive ANP concentration in atria, Sakamoto's
method [23, 24] of extraction was used.
Radioimtnunoassay of rat a trial natriuretic pep tide
a-Human atrial natriuretic peptide (a-hANP, Peptide insti-
tute Inc., Japan) was conjugated to bovine thyroglobulin
(Sigma) using glutaraldehyde [22]. Conjugated a-hANP was
injected into New Zealand white rabbits with Freund's adjuvant
every month and bled two weeks after each injection.
a-hANP was iodinated by the lodogen method (lodo-gen,
Pierce, Illinois, USA) as previously described [25]. The labelled
a-hANP was purified by applying the reaction mixture to a
Sep-Pak cartridge (Waters) and eluating the labelled peptide
with a gradient solution of methanol (0 to 80%) in 0.1%
trifluoroacetic acid. The specific activity of 125Ja-hANP ranged
from 800 to 1100 Ci/sg.
The standard buffer for radioimmunoassay was 0.1 M Tris-
HCI buffer, pH 7.4, containing 0.1% bovine serum albumin,
aprotinin (500 KIU/ml, Bayer), soybean trypsin inhibitor (0.01
mg/ml), 0.01% Triton-x (Packard, Illinois, USA), I mivi sodium
3 30 300 3000 pg/tube
x16 x4 xl plasma Dilution
x2560 x640 x160 atria range
Fig. 1. Typical standard curves of a-hANP and s-rANP and serial
dilution curves of atrial and plasma extracts. bound/total count.
Symbols are: (0) rat plasma extract; (•) a-hANP standards; ()
a-rANP standard; (A) rat atrial extract.
EDTA and 0.02% sodium azide. All reagents were dissolved in
this solution.
The radioimmunoassay incubation mixture consisted of 50 pA
of standard a-hANP, a-rANP or sample, 100 pi of a final
1:52000 dilution of antiserum, and 100 pA of '251-a-hANP. The
antibody bound '251-a-hANP was separated from free '25I-a-
hANP by the second antibody method. Immunoreactive ANP
concentration was calculated from the standard curves of
a-rANP. Using this procedure, the lowest concentration of
a-rANP that could be detected was 4 pg/tube. The 50% inter-
cept was 50 pg/mI. The inter- and intra-assay variations were
16.3% (N = 10) and 5.3% (N = 10), respectively. The cross—
reactivity tested against a-hANP with different fragments of
ANP was: [a-rANP (rat, l-28):65%, ANF-Merk (rat,
3-28):60%,. °Tyr-Atriopeptin II (rat, Tyr-5-27):60%, Auriculin
A(rat, 4-27):60%, Auriculin B (rat, 4-28):60%. This radio-
immunoassay detects not only a-rANP but also other peptides
with NH2-terminal extension such as /3- and y-rANP. Serial
dilution of the atrial and plasma extracts showed parallelism to
the synthetic ANP standards (Fig. I). The extract of the atria
from individual rats was diluted 1:800 for ANP measurements.
This dilution was calculated from a study using serial dilution of
atrial extract measured in the radioimmunoassay as shown in
Figure 1.
Electronic microscopy study in the atriu,n
Hydrated LE and DI rats were used throughout the study.
The anaesthetized animals (pentobarbital sodium, 60 p.g/kg,
Abbott Laboratories, IP) were perfused with 0.1 M phosphate
buffer into the aorta under constant pressure. After approxi-
mately 60 seconds of flushing with the buffer, approximately
250 ml of fixative (1.25% glutaraldehyde in 0.1 M phosphate
buffer) was washed through before the perfusion was stopped.
The fixed heart was then removed and small pieces of atrial
tissue placed in cold fixative overnight. After overnight fixation
in glutaraldehyde the tissue was processed routinely for embed-
ding in Sporis resin. Sections were cut on an LKB Ultratome III
(—0.05 pf Thin sections were stained with uranyl nitrate and
lead citrate for viewing on a Siemens Elmiskop 102 electron
microscope at 60 kV.
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Table 1. Plasma vasopressin, plasma renin activity, plasma
osmolality and hematocrit in normal LE, DI and
dehydrated LE rats
Normal LE Non-treated Dl Dehydrated LE(N=6) (N=6) (N=6)
Plasma AVP 1.7 0.3 ND 20.4 0.8"
pg/mi
Plasma renin 5.0 0.9 8.4 l.0 34.5 4.7"
activity
ng Al/mi/hr
Plasma 286.8 1.5 295.0 l.9 297.0 l.4a
osmolality
mOsmol/kg H20
Hematocrit 40.6 0.6 40.9 0.7 46.4 0.7
ND, not detected.
a and b significant difference from normal LE rats values with
P < 0.05 and P < 0.01, respectively
Statistical analysis
All values were expressed as mean SE. One way analysis of
variance and Newman—Keule's multiple comparison were used
for statistical analysis in this study. Only P values less than 0.05
were considered significant.
Results
After 72 hours dehydration, significant increases in plasma
AVP levels, plasma osmolality and plasma renin activity were
observed (Table 1). There was also a large increase in im-
munoreactive ANP content in atria from 60.4 8.2 j.tg/g wet
weight atria (mean SE, N = 12) to 178.2 30.4 (N = 12; P <
0.001). Plasma immunoreactive ANP decreased from 82.4 8.2
pg/mi (N = 12) to 61.9 5.9 (N = 12) but this was not
statistically significant as shown in Figure 2. No ANP immuno-
reactivity was detected in the ventricular homogenates from LE
or DI rats.
Atrial immunoreactive ANP concentration in DI rats (100.6
13.2 p.g/g, N = 12) was slightly but not significantly higher than
that in LE rats. There was no difference in plasma immunoreac-
tive ANP levels between DI (100.2 11.9 pg/mI, N = 12) and
LE rats. In DI rats, no vasopressin was detected in the plasma
but plasma renin activity was higher than that of normal LE
(Table 1).
Infusion of AVP or DDAVP into DI rats for seven days
produced partial correction of their water balance, including
increased body weight, fall in water intake and urine volume,
and increase in urinary osmolality towards normal (Table 2).
There was no difference in these parameters between the AVP
or the DDAVP infused groups. Plasma renin activity was
suppressed by AVP to a level similar to that in normal LE rats
(Tables I and 2). However, it was not changed by DDAVP.
Plasma levels of AVP in AVP infused DI rats was 8.7 1.0
pg/mI compared with 1.7 0.3 for normal LE rats.
Infusion of AVP and DDAVP into the DI rats significantly (P
< 0.05) reduced the atrial immunoreactive ANP content and
also significantly increased the plasma immunoreactive ANP
concentration (Fig. 3). The atrial immunoreactive ANP levels of
the AVP or DDAVP-infused DI rats was 53.8 4.4, and 53.2
8.2 respectively, being no different from levels in the normal LE







Fig. 2. Immunoreactive ANP content of plasma airia and from normal
LE, and LE rats dehydrated for 72 hours, N = 12. Significant difference
from normal LE rats value with * < 0.001.
Table 2. Effects of AVP and DDAVP infusion on metabolic balance,
plasma renin activity and hematocrit in Dl rats
Control AVP DDAVP(N6) (N=6) (N=6)
Body weight g 6.2 1.7 24.0 3.5" 13.3 2.7a
Water intake 880.8 43.2 104.2 6.8" 100.2 l2.7a
mi/kg/day
Urine flow 824.8 42.0 60.0 11.3" 52.8 ll.8'
mi/kg/day
Urine osmolality 126.3 4.8 1384.0 161.7" 1622.0 239.6"
mOsmoi/kg 1120
Plasma renin 8.4 1.0 5.7 0.9k 9.9 1.2
activity
ng/Al/mi/h
1-lematocrit 40.9 0.7 40.8 0.9 40.8 0.7
a and "significant difference from control Dl rat values with P < 0.05
and P < 0.01, respectively
orDDAVPinfusedDlratswas 171.3 18.1 pg/mI, 179 24.6,
respectively, being significantly higher than normal LE rats as
well as control DI rats.
On electron microscopy, osmiophilic spherical accumula-
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Golgi apparatus in a paranuclear situation. With glutaraldehyde
fixation the bodies were relatively homogenous and occasion-
ally membranes could be visualized. There were no discernable
differences between the numbers and dimensions of the struc-
tures between LE and DI rats (Fig. 4).
Discussion
Peptides with natriuretic activity are stored within specific
atrial granules [3—5] and, at least in rats, the granularity as well
as immunoreactive ANP in atria increase during water depriva-
tion and sodium restriction [5, 6]. ANP has been shown to be
released from the heart and to be present in the circulation [18,
22], however, very little is known about the mechanisms
controlling its synthesis, storage and release. Our result con-
firms that immunoreactive ANP concentration in atria of dehy-
drated LE rats is higher than controls. However, plasma levels
were not significantly different even though they tended to be
lower. This would be compatible with a low basal secretion rate
of ANP from the heart such that a decrease in extracellular
volume caused by dehydration decreases the release of ANP
from atria with an increase in atrial ANP concentration. Lang et
Fig. 4. A. Atrial muscle from LE rat. Osmiophilic inclusion bodies
lying among paler mitochondria to one side of the cell nucleus. B. Atrial
muscle from DL rat. The bodies show no apparent differences in size
and numbers from those in LE rats.
al have reported that volume loaded rats had high plasma ANP
[18]. Furthermore, in studies using a rat heart lung preparation,
Dietz has found that ANP release responded to changes in
central venous pressure [26]. These observations are compati-
ble with our results. The observations in regard to volume in the
DI rat are difficult to interpret. There is some doubt about
whether the DI rat is volume deplete [27]. It is interesting that
the plasma and atrial ANP levels were not different from a
normal LE rat. However, replacement therapy with AVP or
DDAVP, which would expand its extracellular volume, led to a
increase in plasma ANP and a fall in atrial ANP. The reciprocal
changes in atrial and plasma ANP support the thesis that similar
to other hormone systems, atrial stores are a reflection of
secretion rather than biosynthesis. The available evidence
suggests that atrial ANP concentration is related to the extra-
cellular fluid volume, This could be the direct effect of an atrial
"stretch" receptor or alternatively may be hormonally or
neurally mediated. One possibility is that the ANP releasing
mechanism is directly suppressed by circulating vasopressin,
since vasopressin concentration rises during water deprivation.
Indeed, atrial immunoreactive ANP content was increased and
plasma immunoreactive ANP levels tended to decrease after
dehydration accompanyied by the increase in plasma AVP
















Fig. 3. Changes of plasma and atrialANP content of DI rats, N = 12.
Arginine vasopressin or DDAVP were infused intravenously at 2.0
ng/kg/min for 7 days. * Significant difference from control Dl rats values
with P < 0.05.
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munoreactive ANP content was not different compared with
normal LE rats. Moreover, AVP caused a decrease in atrial
immunoreactive ANP of DI rats and an increase in plasma
immunoreactive ANP concentration. These observations sug-
gest that AVP is not an important inhibitor of ANP release in
vivo.
On the other hand, Sonnenberg and Veress reported that
AVP stimulated ANP release in vitro from incubated atria in
addition to a-adrenergic agonists and muscarinic cholinergic
agents [28]. In DI rats, the treatment with AVP decreased atrial
immunoreactive ANP and increased plasma immunoreactive
ANP concentration. However, not only AVP but also DDAVP,
a vasopressin analogue with potent antidiuretic activity but with
minimal vasoconstrictor action [29] caused the decrease in
atrial immunoreactive ANP and the increase in plasma im-
munoreactive ANP levels. This effect of DDAVP was probably
secondary to its effects on blood volume rather than a direct
atrial effect since it was not reported to increase ANP release
from incubated atria in vitro [28]. Furthermore, the results
obtained with dehydrated LE rats do not support a role for AVP
in stimulating ANP release. Despite the elevation of plasma
AVP levels, atrial immunoreactive ANP concentration in-
creased and plasma immunoreactive ANP concentration de-
creased.
We demonstrated that even in DI rats, genetically lacking
vasopressin, atria had specific granules which contained ANP.
There was no significant difference in atrial immunoreactive
ANP content between DI rats and LE rats, and no histological
difference in atrial granule content was obvious. Furthermore,
no difference in plasma immunoreactive ANP concentration
was observed. Increased atrial ANP concentration measured by
bioassay in both DI rats and dehydrated LE rats has been
reported previously [30].
The suggestion that the renin—angiotensin system may play a
role in controlling ANP release, was also investigated. Plasma
renin activity moved in parallel with atrial immunoreactive
ANP content and in an opposite direction to plasma im-
munoreactive ANP levels in hydrated and dehydrated LE rats,
as well as AVP infused DI rats. However, in control DI rats,
plasma renin activity was higher than normal LE rats with no
significant difference in plasma immunoreactive ANP levels.
Furthermore, in DI rats infused with DDAVP, atrial im-
munoreactive ANP content was decreased and plasma im-
munoreactive ANP concentration was increased without nor-
malizing plasma renin activity. Renin secretion is very sensitive
to sodium and water balance, so the changes in plasma renin
activity may reflect the water balance in these groups. An
inhibitory effect on renin secretion by AVP but not DDAVP has
been reported in conscious dogs [311. Also we confirmed that,
in DI rats, renin secretion is suppressed by AVP but not
DDAVP. In view of the changes in plasma renin activity of each
group, it is unlikely that the renin—angiotensin system directly
affects ANP release from atria.
From our results we conclude that water balance appears to
be an important factor controlling ANP release in vivo. How-
ever, this is probably through either a direct atrial volume—
stretch mechanism or osmolality rather than via changes in
vasopressin or the renin—angiotensin system.
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